Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115345 · ClinicalTrials.gov registry record · Phase 1
A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).
A Phase 1 study, sponsored by Prokidney.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04115345 is a Phase 1 study that has completed, run by Prokidney. The registered enrollment target is 6 participants.
The verdict
NCT04115345, a Phase 1 study, has completed, sponsored by Prokidney.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A phase 1, open-label safety, tolerability and early efficacy study of a Renal Autologous Cell Therapy (REACT) in patients with Chronic Kidney Disease from Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04115345
The ClinicalTrials.gov registry entry for NCT04115345 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT04115345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04115345 about?
NCT04115345 is a clinical study titled "A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).". A phase 1, open-label safety, tolerability and early efficacy study of a Renal Autologous Cell Therapy (REACT) in patients with Chronic Kidney Disease from Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)
What is the current status of trial NCT04115345?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-08-13. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04115345?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04115345?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.